Molecular Templates Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.8032
- Today's High:
- $7.97
- Open Price:
- $7.97
- 52W Low:
- $4.65
- 52W High:
- $12.75
- Prev. Close:
- $7.99
- Volume:
- 1650
Company Statistics
- Market Cap.:
- $42.94 million
- Book Value:
- -2.31
- Revenue TTM:
- $50.35 million
- Operating Margin TTM:
- -88.76%
- Gross Profit TTM:
- $-45968000
- Profit Margin:
- -92.78%
- Return on Assets TTM:
- -31.66%
- Return on Equity TTM:
- -538.17%
Company Profile
Molecular Templates Inc had its IPO on 2005-02-04 under the ticker symbol MTEM.
The company operates in the Healthcare sector and Biotechnology industry. Molecular Templates Inc has a staff strength of 111 employees.
Stock update
Shares of Molecular Templates Inc opened at $7.97 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $7.8 - $7.97, and closed at $7.83.
This is a -2% slip from the previous day's closing price.
A total volume of 1,650 shares were traded at the close of the day’s session.
In the last one week, shares of Molecular Templates Inc have slipped by -7.99%.
Molecular Templates Inc's Key Ratios
Molecular Templates Inc has a market cap of $42.94 million, indicating a price to book ratio of 5.9989 and a price to sales ratio of 0.7223.
In the last 12-months Molecular Templates Inc’s revenue was $50.35 million with a gross profit of $-45968000 and an EBITDA of $-37004000. The EBITDA ratio measures Molecular Templates Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Molecular Templates Inc’s operating margin was -88.76% while its return on assets stood at -31.66% with a return of equity of -538.17%.
In Q2, Molecular Templates Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 55.4%.
Molecular Templates Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-12.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Molecular Templates Inc’s profitability.
Molecular Templates Inc stock is trading at a EV to sales ratio of 0.1254 and a EV to EBITDA ratio of 0.0611. Its price to sales ratio in the trailing 12-months stood at 0.7223.
Molecular Templates Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $35.51 million
- Total Liabilities
- $26.94 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $17000
- Dividend Payout Ratio
- 0%
Molecular Templates Inc ended 2024 with $35.51 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.51 million while shareholder equity stood at $-8678000.00.
Molecular Templates Inc ended 2024 with $19000.00 in deferred long-term liabilities, $26.94 million in other current liabilities, 56000.00 in common stock, $-444791000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.95 million and cash and short-term investments were $4.95 million. The company’s total short-term debt was $2,349,000 while long-term debt stood at $0.
Molecular Templates Inc’s total current assets stands at $11.82 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $274000.00 compared to accounts payable of $4.67 million and inventory worth $3.89 million.
In 2024, Molecular Templates Inc's operating cash flow was $0 while its capital expenditure stood at $17000.
Comparatively, Molecular Templates Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $7.83
- 52-Week High
- $12.75
- 52-Week Low
- $4.65
- Analyst Target Price
- $37.5
Molecular Templates Inc stock is currently trading at $7.83 per share. It touched a 52-week high of $12.75 and a 52-week low of $12.75. Analysts tracking the stock have a 12-month average target price of $37.5.
Its 50-day moving average was $8.3 and 200-day moving average was $7.16 The short ratio stood at 4.76 indicating a short percent outstanding of 0%.
Around 569.4% of the company’s stock are held by insiders while 5321.4% are held by institutions.
Frequently Asked Questions About Molecular Templates Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.